高级检索
当前位置: 首页 > 详情页

Combination Of STING Agonist And CXCR3 Antagonist Disrupts Immune Tolerance To Overcome Anti-PD-L1 Resistance In Lung Adenocarcinoma Under Oxidative Stress

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China [2]Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, College of Polymer Science and Engineering, [3]Laboratory of Infectious Diseases and Vaccine, West China Hospital, Sichuan University, Chengdu, China [4]Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA [5]Division of Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China [6]Department of General Surgery, Sir Run Shaw Hospital, Zhejiang University, Hangzhou, China
出处:
ISSN:

摘要:
We investigated the role of the STING1-CXCR3 axis using database data and verified it in a mouse model bearing Lewis lung carcinoma (LLC) cells exposed to hydrogen peroxide (H2O2). Mice were treated with STING agonist liposomes (STING-Lip), anti-programmed death-ligand 1 (PD-L1), or STING-Lip+anti-PD-L1. The database data revealed that immune response pathways were enriched in patients with lung adenocarcinoma with upregulated STING1 signaling. Upregulated STING1 signaling was associated with a high abundance of immunoregulatory and effector molecules, cytokines, activated CD8+ T cells, and M1 macrophages in patients with lung adenocarcinoma. In this study, H2O2-treated LLC cells promoted an immunosuppressive microenvironment and enhanced tumor growth in mice. STING-Lip inhibited distant, untreated, and H2O2-induced LLC growth by activating systemic immunity. STING-Lip+anti-PD-L1 failed to slow distant and untreated LLC growth, whereas STING-Lip+anti-PD-L1+CXCR3 antagonist inhibited distant tumor growth in mice. The combination of STING1 activation and CXCR3 inhibition may be a novel immunotherapeutic strategy to overcome immune checkpoint inhibitor resistance in lung adenocarcinoma by activating systemic immunity in the tumor microenvironment under oxidative stress.Copyright © 2022 Elsevier B.V. All rights reserved.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 生物学
小类 | 3 区 遗传学
最新[2023]版:
大类 | 3 区 生物学
小类 | 3 区 遗传学
JCR分区:
出版当年[2023]版:
Q2 GENETICS & HEREDITY
最新[2023]版:
Q2 GENETICS & HEREDITY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China [2]Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, College of Polymer Science and Engineering,
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号